FY2029 EPS Estimates for C4 Therapeutics Cut by Analyst

Key Points

• Brookline Capital Markets lowered C4 Therapeutics’ FY2029 EPS estimate to $5.90 from $6.14, while forecasting FY2030 EPS of $22.46. The current-year consensus remains a loss of $0.87 per share.
• C4 Therapeutics beat quarterly expectations, reporting an EPS loss of $0.18 versus the $0.23 consensus estimate and revenue of $6.64 million versus expectations of $4.00 million.
• The stock opened at $3.87, with a $1.69–$5.17 52-week range and a market capitalization of approximately $427.9 million. Analysts collectively rate the shares “Moderate Buy,” with a consensus price target of $7.75, despite Weiss Ratings maintaining a “sell” rating.

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Research analysts at Brookline Capital Markets dropped their FY2029 earnings per share estimates for C4 Therapeutics in a research report issued on Tuesday, August 11th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $5.90 per share for the year, down from their previous estimate of $6.14. The consensus estimate for C4 Therapeutics' current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics' FY2030 earnings at $22.46 EPS.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of C4 Therapeutics in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, C4 Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.

C4 Therapeutics Price Performance

CCCC opened at $3.87 on Wednesday. C4 Therapeutics has a fifty-two week low of $1.69 and a fifty-two week high of $5.17. The firm has a market capitalization of $427.91 million, a price-to-earnings ratio of -3.25 and a beta of 2.91. The company's 50 day moving average price is $3.91 and its two-hundred day moving average price is $3.16.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative return on equity of 50.68% and a negative net margin of 297.76%.

Institutional Investors Weigh In On C4 Therapeutics

Institutional investors have recently modified their holdings of the company. SummitTX Capital L.P. acquired a new stake in shares of C4 Therapeutics during the first quarter worth $28,000. CTC Alternative Strategies Ltd. acquired a new position in C4 Therapeutics in the first quarter valued at $28,000. Zacks Investment Management acquired a new position in C4 Therapeutics in the third quarter valued at $29,000. Delta Investment Management LLC bought a new stake in C4 Therapeutics during the fourth quarter valued at $38,000. Finally, Virtu Financial LLC bought a new stake in C4 Therapeutics during the fourth quarter valued at $39,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source